The Treat and Reduce Obesity Act of 2025 amends the Social Security Act to let the Secretary of HHS expand Medicare coverage for intensive behavioral therapy (IBT) for obesity to a wider set of providers — including physician assistants, nurse practitioners, clinical psychologists, registered dietitians, and approved community‑based lifestyle programs — provided services are coordinated with a referring physician and furnished in specified settings. The bill also inserts an exception into the Medicare Part D drug exclusion language so that drugs used to treat obesity or for weight loss management for overweight patients with comorbidities can be covered under Part D, with that change taking effect for plan years starting two years after enactment.
The legislation matters for a range of actors: it creates new billing and care pathways for non‑physician clinicians and community programs; it changes the coverage landscape for pharmaceutical sponsors of obesity medications; and it poses an immediate implementation and cost question for CMS and Part D plan sponsors, who will need to adapt formularies, payment rules, and oversight practices to accommodate both therapy and drug coverage changes.
At a Glance
What It Does
Authorizes the Secretary to cover intensive behavioral therapy for obesity when furnished by a broader list of clinicians and approved community programs, subject to referral and coordination requirements and HIPAA‑compliant settings; amends Part D exclusion rules to allow coverage of obesity and certain weight‑loss medications, effective for plan years beginning two years after enactment. It also requires HHS to report to Congress within one year and biennially thereafter on implementation.
Who It Affects
Directly affects Medicare beneficiaries with obesity or overweight and related comorbidities, non‑physician clinicians (PAs, NPs, clinical psychologists, registered dietitians), community lifestyle counseling programs seeking Medicare reimbursement, Part D plan sponsors and pharmacy benefit managers, and drug manufacturers of obesity therapies.
Why It Matters
Shifts how obesity care can be delivered within Medicare by broadening provider eligibility and authorizing Medicare drug coverage for obesity treatments—potentially increasing utilization while integrating community programs into clinical care. Compliance, coding, and formulary changes will be required, and program spending is likely to rise in the near term.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill makes two operational changes to Medicare’s statutory framework. First, it modifies the definition of qualified providers able to furnish intensive behavioral therapy (IBT) for obesity under section 1861(ddd) by adding a new paragraph that explicitly permits physicians who are not already designated as primary care physicians and a list of other providers — physician assistants, nurse practitioners, clinical nurse specialists, clinical psychologists, and registered dietitians — to furnish IBT.
The Secretary retains discretion to grant coverage, but the new language opens the door for many clinicians who were previously ineligible to be paid by Medicare for this service.
Second, the bill permits evidence‑based, community‑based lifestyle counseling programs to provide IBT if they obtain Secretary approval. Coverage for services delivered by non‑physician clinicians or community programs is conditioned on a referral from and coordination with a physician or primary care practitioner; the bill also requires communication back to the referring clinician of recommendations or treatment plans.
The statute enumerates permitted furnishing locations (office, hospital outpatient department, HIPAA‑compliant community sites) while giving the Secretary authority to specify additional settings.On the drug side, the bill amends the Part D statutory exclusion language to carve out obesity and certain weight‑loss management medications from the list of otherwise excluded drugs. The change references existing statutory definitions (cross‑referencing provisions in 1861(yy)) and delays practical effect until plan years beginning on or after two years after enactment, giving Part D sponsors time to adapt formularies and utilization management policies.
Finally, HHS must report to Congress within 1 year and then every 2 years on implementation steps taken and recommendations for better coordination across federal programs relevant to treating and preventing adult obesity.Collectively, the bill is designed to increase access to both behavioral treatments and pharmacologic options for Medicare beneficiaries, while embedding a requirement that new provider types coordinate care with physicians. The statute is permissive — it authorizes coverage rather than mandating it — but it creates the statutory basis for CMS to write payment, credentialing, and program standards that could materially change who gets paid and how obesity care is delivered in Medicare.
The Five Things You Need to Know
The bill adds a new paragraph to 42 U.S.C. 1395x(ddd) authorizing coverage of intensive behavioral therapy for obesity when furnished by physicians not currently labeled as 'qualified primary care physicians' and by PAs, NPs, clinical nurse specialists, clinical psychologists, and registered dietitians.
Evidence‑based, community‑based lifestyle counseling programs become eligible to deliver IBT under Medicare if approved by the Secretary; coverage for these programs requires referral and active coordination with a physician or primary care practitioner.
The bill amends the Part D exclusion statute to permit coverage of drugs used to treat obesity or for weight‑loss management in overweight patients with comorbidities (cross‑referencing definitions in 1861(yy)), with the change applying to plan years beginning two years after enactment.
When non‑physician clinicians or community programs furnish IBT, the bill requires those providers to communicate recommendations and treatment plans back to the referring physician to ensure collaborative care.
HHS must submit an initial report to Congress within one year describing implementation steps and thereafter every two years, including recommendations for better coordination of federal programs and clinical care related to adult obesity.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Congressional findings on obesity and Medicare impact
This section collects epidemiologic and fiscal findings (obesity prevalence among older adults, attributable deaths, and historical Medicare spending estimates) to justify the statutory changes that follow. The findings frame obesity as a growing driver of chronic disease and program costs, which the remainder of the bill treats as the policy problem to address.
Expands which providers can be paid for intensive behavioral therapy
Subparagraph (4) authorizes the Secretary to extend IBT coverage beyond primary care physicians to other physicians and a specified list of non‑physician clinicians and clinical psychologists and registered dietitians. It also permits approved evidence‑based community lifestyle programs to furnish IBT. For non‑physician and community providers the bill conditions coverage on referral from, and coordination with, a physician or primary care practitioner and limits allowable furnishing locations to office settings, hospital outpatient departments, or HIPAA‑compliant community sites (with Secretary discretion to add settings). The most practical implications are credentialing, creation of benefit descriptions, billing codes, and supervision or collaborative practice rules that CMS will need to specify.
Allows Part D coverage of obesity and certain weight‑loss drugs
This amendment inserts an exception to the list of excluded drugs so that medications used to treat obesity or for weight management in overweight patients with comorbidities are eligible under Part D. The statutory change refers back to obesity/overweight definitions in 1861(yy) and phases in for plan years beginning two years after enactment. In practice, Part D sponsors will need to decide formulary placement, prior authorization criteria, and utilization management approaches once CMS issues guidance implementing the change.
HHS implementation reporting requirement
The Secretary must report to Congress within one year and then biennially on steps taken to implement the Act and provide recommendations for leveraging intra‑ and interagency programs to support research, clinical care, and prevention. The reporting mechanism is the bill’s accountability lever and will be the principal means Congress receives programmatic detail, cost estimates, and policy recommendations following statutory authorization.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries with obesity or overweight and comorbidities — gain potential access to a wider range of clinicians and approved community lifestyle programs for intensive behavioral therapy and to Part D–covered obesity medications.
- Non‑physician clinicians (physician assistants, nurse practitioners, clinical psychologists, registered dietitians) — open up new revenue streams by furnishing IBT that Medicare may cover, subject to coordination rules and CMS billing policies.
- Evidence‑based community lifestyle programs — become candidates for Medicare reimbursement if they obtain Secretary approval and meet privacy/setting requirements, creating a pathway to scale community interventions.
- Manufacturers of GLP‑1s and other obesity medications — stand to gain larger market access through Part D coverage for indicated obesity/weight‑loss uses once the change takes effect.
- Primary care practices and health systems — can leverage allied clinicians and community programs to expand multidisciplinary obesity care and potentially reduce downstream chronic disease burden.
Who Bears the Cost
- Medicare program (CMS/Trust Funds) — faces likely near‑term increases in utilization and spending from expanded IBT access and the introduction of Part D coverage for obesity drugs, affecting actuarial and budget projections.
- Part D plan sponsors and pharmacy benefit managers — will need to update formularies, utilization management, and premium/benefit designs to accommodate new obesity drug coverage and may absorb higher short‑term drug costs.
- CMS/HHS operations — must craft rulemaking, approval criteria for community programs, billing guidance, and oversight processes, which will require administrative resources and potentially new contractor work.
- Community providers and smaller programs seeking approval — must shoulder compliance costs (HIPAA controls, documentation, reporting) to meet Secretary standards and become eligible for Medicare reimbursement.
- Referring clinicians and primary care practices — may face increased coordination burdens (referrals, receiving and acting on treatment plans), without explicit new payment for care coordination in the bill.
Key Issues
The Core Tension
The bill pits expanded clinical access against program affordability and administrability: it authorizes broader provider participation and Part D drug coverage to improve obesity care, but those same provisions are likely to increase Medicare spending and require significant CMS rulemaking and oversight resources—forcing a trade‑off between improving access now and controlling program costs and complexity.
The central implementation challenge is operational: the statute authorizes coverage but leaves critical details to the Secretary. CMS will need to define approval criteria for evidence‑based community programs, set billing and supervision rules for the newly eligible provider types, and issue guidance on acceptable furnishing locations and privacy safeguards.
Those choices determine whether expanded access becomes real or remains nominal. Similarly, the Part D amendment changes eligibility for coverage but does not specify formulary placement, prior authorization standards, step therapy rules, or cost‑sharing protections, leaving plan sponsors and CMS to reconcile clinical guidance, budget constraints, and benefit design.
From a fiscal and program integrity perspective, authorizing Part D coverage of obesity medications risks substantial near‑term increases in drug spending—especially if high‑cost therapies are widely prescribed—while any long‑term savings from reduced chronic disease are uncertain and will depend on adherence, patient selection, and whether behavioral supports are consistently delivered alongside medication. The bill’s coordination requirement (communication back to referring physicians) advances continuity of care but creates administrative friction; it is unclear whether the statute contemplates specific timelines, documentation standards, or payment for that coordination.
Finally, the Secretary’s approval role for community programs is a double‑edged sword: it can maintain quality but also create barriers to entry if the criteria are opaque or costly to meet.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.